Association Between Platelet Count and Other Factors in Patients with Stage-IV Non-Small Cell Lung Cancer

Beauty Saha; Muhammad Rafiqul Islam; Nazma Azim; Salman Bashar Al Aub; Rashedul Islam; Ahmed Jabeer

doi:doi:10.11648/j.ijcocr.20230803.14

| Peer-Reviewed

Association Between Platelet Count and Other Factors in Patients with Stage-IV Non-Small Cell Lung Cancer

Beauty Saha, Muhammad Rafiqul Islam, Nazma Azim, Salman Bashar Al Aub, Rashedul Islam, Ahmed Jabeer

Published in International Journal of Clinical Oncology and Cancer Research (Volume 8, Issue 3)

Received: 22 July 2023 Accepted: 21 August 2023 Published: 18 September 2023

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Background: Stage IV non-small-cell lung cancer (NSCLC) means a disease that has spread from the lungs to distant areas of the body like the liver, brain, or bones. An increased platelet count can accompany various cancers including lung cancer. This finding has recently been suggested to indicate a poor prognosis. Preconception on the relation between platelet count and other associated factors in patients with stage-IV non-small cell lung cancer may be a potential associated indicator in managing such patients. Aim of the study: This study aimed to evaluate the relationship between platelet count and other associated factors in patients with stage-IV non-small cell lung cancer (NSCLC). Methods: This prospective observational study was conducted at the National Institute of Cancer Research & Hospital (NICRH), Dhaka, Bangladesh during the period from September 2019 to August 2020. A total of 108 patients were enrolled purposively. Detailed history taking and thorough physical examination was done along with relevant investigations. Data were collected by semi-structured questionnaire and analysis was done by SPSS, version 21.0. Results: The mean age of the patients was found 56.4±12.2 years and the majority (79.6%) of patients were male. The highest number of participants (40.7%) were symptomatic; in bed, >50% of the day, almost two-thirds (59.3%) had <5% weight loss, and almost three fourth (69.4%) had squamous cell carcinoma. At the time of the first assessment, 75 (69.4%) patients had normal and 33 (30.6%) had elevated platelet count levels, age, sex, and histological type were statistically not significant between normal and elevated platelet count level groups. But performance status and weight loss were statistically significant (p<0.05) between the two groups. According to univariate analysis, age, performance status at presentation, weight loss of more than 10% for 3 months and platelet count before the start of treatment were all significant predictors for overall survival. Conclusion: As per the findings of this study we can conclude that there has no significant correlation of platelet count with age, sex or histological types of NSCLC patients. But with performance status and weight loss, there may have a statistically significant correlation in such patients.

Published in	International Journal of Clinical Oncology and Cancer Research (Volume 8, Issue 3)
DOI	10.11648/j.ijcocr.20230803.14
Page(s)	64-71
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Non-Small Cell Lung Cancer, Platelet Count, Prognostic Factor, Stage-IV NSCLC

References

[1]	Torre, L. A., Siegel, R. L., Ward, E. M. and Jemal, A., 2016. Global cancer incidence and mortality rates and trends-an update. Cancer Epidemiology and Prevention Biomarkers, 25 (1), pp. 16-27.
[2]	Brzezniak, C., Churinga, J. Thomas, A. (2001) Non-small cell lung cancrinite handbook of clinical oncology, 5thed. (Abraham J. and Gully J. L., eds), Wolter Kluwer, Market Street, Philadelphia, pp. 26-42.
[3]	Mohan, A., Latifi, A. N. and Guleria, R., 2016. Increasing incidence of adenocarcinoma lung in India: Following the global trend. Indian journal of cancer, 53 (1), p. 92.
[4]	Zou, X. N., Lin, D. M., Xia, W. A. N., Ann, C. H. A. O., Feng, Q. F., Zhen, D. A. I., Yang, G. H. and Ning, L. V., 2014. Histological subtypes of lung cancer in Chinese males from 2000 to 2012. Biomedical and Environmental Sciences, 27 (1), pp. 3-9.
[5]	Goldstraw, P., et al. "Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumors. J Thorac Oncol 2007; 2 (8): 706–714 The above article ran in the August 2007 issue without showing the figures on page 711 in color. We regret any inconvenience this may have caused. In this issue, we present Figures 2 and 3 from that article in full color." Journal of Thoracic Oncology 2.10 (2007): 985.
[6]	Ashworth, A. B., Senan, S., Palma, D. A., Riquet, M., Ahn, Y. C., Ricardi, U., Congedo, M. T., Gomez, D. R., Wright, G. M., Melloni, G. and Milano, M. T., 2014. An individual patient data meta-analysis of outcomes and prognostic factors after treatment of oligometastatic non–small-cell lung cancer. Clinical lung cancer, 15 (5), pp. 346-355.
[7]	Richard, P. J. and Rengan, R., 2016. Oligometastatic non-small-cell lung cancer: current treatment strategies. Lung Cancer: Targets and Therapy, 7, p. 129.
[8]	Berghmans, T., Paesmans, M. and Sculier, J. P., 2011. Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables. Therapeutic advances in medical oncology, 3 (3), pp. 127-138.
[9]	Riess, L., 1872. Zur pathologischen anatomie des blutes. Arch. Anat. Physiol. Wissensch Medical, 39, pp. 237-240.
[10]	Levin, J. and Conley, C. L., 1964. Thrombocytosis associated with malignant disease. Archives of internal medicine, 114 (4), pp. 497-500.
[11]	Edwards, R. L., Rickles, F. R., Moritz, T. E., Henderson, W. G., Zacharski, L. R., Forman, W. B., Cornell, C. J., Forcier, R. J., O’Donnell, J. F., Headley, E. and Kim, S. H., 1987. Abnormalities of blood coagulation tests in patients with cancer. American journal of clinical pathology, 88 (5), pp. 596-602.
[12]	Chadha, A. S., Kocak-Uzel, E., Das, P., Minsky, B. D., Delclos, M. E., Mahmood, U., Guha, S., Ahmad, M., Varadhachary, G. R., Javle, M. and Katz, M. H., 2015. Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer. Acta oncologica, 54 (7), pp. 971-978.
[13]	Feng, Z., Wen, H., Bi, R., Duan, Y., Yang, W. and Wu, X., 2016. Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients. BMC Cancer, 16 (1), p. 43.
[14]	Mitus, A. J. and Schafer, A. I., 1990. Thrombocytosis and thrombocythemia. Hematology/oncology clinics of North America, 4 (1), pp. 157-178.
[15]	World Medical Association. (‎2001) ‎. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bulletin of the World Health Organization, 79 (‎4)‎, 373 - 374. World Health Organization. https://apps.who.int/iris/handle/10665/268312.
[16]	Voigt, Paul, and Axel von dem Bussche. "Enforcement and fines under the GDPR." The EU General Data Protection Regulation (GDPR). Springer, Cham, 2017. 201-217.
[17]	Davidov, D., 2014. Thrombocytosis as a prognostic factor for survival in patients with advanced non-small cell lung cancer treated with first-line chemotherapy. Journal of IMAB–Annual Proceeding Scientific Papers, 20 (6), pp. 560-564.
[18]	Maráz, A., Furák, J., Varga, Z., Kahán, Z., Tiszlavicz, L. and Hideghéty, K., 2013. Thrombocytosis has a negative prognostic value in lung cancer. Anticancer Research, 33 (4), pp. 1725-1729.
[19]	Cui, M. M., Li, N., Liu, X., Yun, Z. Y., Niu, Y., Zhang, Y., Gao, B., Liu, T. and Wang, R. T., 2017. Platelet distribution width correlates with the prognosis of non-small cell lung cancer. Scientific reports, 7 (1), pp. 1-6.
[20]	Aoe, K., Hiraki, A., Ueoka, H., Kiura, K., Tabata, M., Tanaka, M. and Tanimoto, M., 2004. Thrombocytosis as a useful prognostic indicator in patients with lung cancer. Respiration, 71 (2), pp. 170-173.

Cite This Article

Plain Text BibTeX RIS

APA Style

Beauty Saha, Muhammad Rafiqul Islam, Nazma Azim, Salman Bashar Al Aub, Rashedul Islam, et al. (2023). Association Between Platelet Count and Other Factors in Patients with Stage-IV Non-Small Cell Lung Cancer. International Journal of Clinical Oncology and Cancer Research, 8(3), 64-71. https://doi.org/10.11648/j.ijcocr.20230803.14

Copy | Download

ACS Style

Beauty Saha; Muhammad Rafiqul Islam; Nazma Azim; Salman Bashar Al Aub; Rashedul Islam, et al. Association Between Platelet Count and Other Factors in Patients with Stage-IV Non-Small Cell Lung Cancer. Int. J. Clin. Oncol. Cancer Res. 2023, 8(3), 64-71. doi: 10.11648/j.ijcocr.20230803.14

Copy | Download

AMA Style

Beauty Saha, Muhammad Rafiqul Islam, Nazma Azim, Salman Bashar Al Aub, Rashedul Islam, et al. Association Between Platelet Count and Other Factors in Patients with Stage-IV Non-Small Cell Lung Cancer. Int J Clin Oncol Cancer Res. 2023;8(3):64-71. doi: 10.11648/j.ijcocr.20230803.14

Copy | Download

@article{10.11648/j.ijcocr.20230803.14,
  author = {Beauty Saha and Muhammad Rafiqul Islam and Nazma Azim and Salman Bashar Al Aub and Rashedul Islam and Ahmed Jabeer},
  title = {Association Between Platelet Count and Other Factors in Patients with Stage-IV Non-Small Cell Lung Cancer},
  journal = {International Journal of Clinical Oncology and Cancer Research},
  volume = {8},
  number = {3},
  pages = {64-71},
  doi = {10.11648/j.ijcocr.20230803.14},
  url = {https://doi.org/10.11648/j.ijcocr.20230803.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcocr.20230803.14},
  abstract = {Background: Stage IV non-small-cell lung cancer (NSCLC) means a disease that has spread from the lungs to distant areas of the body like the liver, brain, or bones. An increased platelet count can accompany various cancers including lung cancer. This finding has recently been suggested to indicate a poor prognosis. Preconception on the relation between platelet count and other associated factors in patients with stage-IV non-small cell lung cancer may be a potential associated indicator in managing such patients. Aim of the study: This study aimed to evaluate the relationship between platelet count and other associated factors in patients with stage-IV non-small cell lung cancer (NSCLC). Methods: This prospective observational study was conducted at the National Institute of Cancer Research & Hospital (NICRH), Dhaka, Bangladesh during the period from September 2019 to August 2020. A total of 108 patients were enrolled purposively. Detailed history taking and thorough physical examination was done along with relevant investigations. Data were collected by semi-structured questionnaire and analysis was done by SPSS, version 21.0. Results: The mean age of the patients was found 56.4±12.2 years and the majority (79.6%) of patients were male. The highest number of participants (40.7%) were symptomatic; in bed, >50% of the day, almost two-thirds (59.3%) had <5% weight loss, and almost three fourth (69.4%) had squamous cell carcinoma. At the time of the first assessment, 75 (69.4%) patients had normal and 33 (30.6%) had elevated platelet count levels, age, sex, and histological type were statistically not significant between normal and elevated platelet count level groups. But performance status and weight loss were statistically significant (p<0.05) between the two groups. According to univariate analysis, age, performance status at presentation, weight loss of more than 10% for 3 months and platelet count before the start of treatment were all significant predictors for overall survival. Conclusion: As per the findings of this study we can conclude that there has no significant correlation of platelet count with age, sex or histological types of NSCLC patients. But with performance status and weight loss, there may have a statistically significant correlation in such patients.},
 year = {2023}
}

Copy | Download

TY - JOUR
T1 - Association Between Platelet Count and Other Factors in Patients with Stage-IV Non-Small Cell Lung Cancer
AU - Beauty Saha
AU - Muhammad Rafiqul Islam
AU - Nazma Azim
AU - Salman Bashar Al Aub
AU - Rashedul Islam
AU - Ahmed Jabeer
Y1 - 2023/09/18
PY - 2023
N1 - https://doi.org/10.11648/j.ijcocr.20230803.14
DO - 10.11648/j.ijcocr.20230803.14
T2 - International Journal of Clinical Oncology and Cancer Research
JF - International Journal of Clinical Oncology and Cancer Research
JO - International Journal of Clinical Oncology and Cancer Research
SP - 64
EP - 71
PB - Science Publishing Group
SN - 2578-9511
UR - https://doi.org/10.11648/j.ijcocr.20230803.14
AB - Background: Stage IV non-small-cell lung cancer (NSCLC) means a disease that has spread from the lungs to distant areas of the body like the liver, brain, or bones. An increased platelet count can accompany various cancers including lung cancer. This finding has recently been suggested to indicate a poor prognosis. Preconception on the relation between platelet count and other associated factors in patients with stage-IV non-small cell lung cancer may be a potential associated indicator in managing such patients. Aim of the study: This study aimed to evaluate the relationship between platelet count and other associated factors in patients with stage-IV non-small cell lung cancer (NSCLC). Methods: This prospective observational study was conducted at the National Institute of Cancer Research & Hospital (NICRH), Dhaka, Bangladesh during the period from September 2019 to August 2020. A total of 108 patients were enrolled purposively. Detailed history taking and thorough physical examination was done along with relevant investigations. Data were collected by semi-structured questionnaire and analysis was done by SPSS, version 21.0. Results: The mean age of the patients was found 56.4±12.2 years and the majority (79.6%) of patients were male. The highest number of participants (40.7%) were symptomatic; in bed, >50% of the day, almost two-thirds (59.3%) had <5% weight loss, and almost three fourth (69.4%) had squamous cell carcinoma. At the time of the first assessment, 75 (69.4%) patients had normal and 33 (30.6%) had elevated platelet count levels, age, sex, and histological type were statistically not significant between normal and elevated platelet count level groups. But performance status and weight loss were statistically significant (p<0.05) between the two groups. According to univariate analysis, age, performance status at presentation, weight loss of more than 10% for 3 months and platelet count before the start of treatment were all significant predictors for overall survival. Conclusion: As per the findings of this study we can conclude that there has no significant correlation of platelet count with age, sex or histological types of NSCLC patients. But with performance status and weight loss, there may have a statistically significant correlation in such patients.
VL - 8
IS - 3
ER -

Copy | Download

Author Information

Beauty Saha

Department of Radiotherapy, Mymensingh Medical College Hospital, Mymensingh, Bangladesh
Muhammad Rafiqul Islam

Department of Medical Oncology, National Institute of Cancer Research and Hospital, Dhaka, Bangladesh
Nazma Azim

National Institute of Cancer Research and Hospital, Dhaka, Bangladesh
Salman Bashar Al Aub

Department of Medical Oncology, National Institute of Cancer Research and Hospital, Dhaka, Bangladesh
Rashedul Islam

Department of Medical Oncology, National Institute of Cancer Research and Hospital, Dhaka, Bangladesh
Ahmed Jabeer

Department of Medical Oncology, National Institute of Cancer Research and Hospital, Dhaka, Bangladesh

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Beauty Saha, Muhammad Rafiqul Islam, Nazma Azim, Salman Bashar Al Aub, Rashedul Islam, et al. (2023). Association Between Platelet Count and Other Factors in Patients with Stage-IV Non-Small Cell Lung Cancer. International Journal of Clinical Oncology and Cancer Research, 8(3), 64-71. https://doi.org/10.11648/j.ijcocr.20230803.14

Copy | Download

ACS Style

Beauty Saha; Muhammad Rafiqul Islam; Nazma Azim; Salman Bashar Al Aub; Rashedul Islam, et al. Association Between Platelet Count and Other Factors in Patients with Stage-IV Non-Small Cell Lung Cancer. Int. J. Clin. Oncol. Cancer Res. 2023, 8(3), 64-71. doi: 10.11648/j.ijcocr.20230803.14

Copy | Download

AMA Style

Beauty Saha, Muhammad Rafiqul Islam, Nazma Azim, Salman Bashar Al Aub, Rashedul Islam, et al. Association Between Platelet Count and Other Factors in Patients with Stage-IV Non-Small Cell Lung Cancer. Int J Clin Oncol Cancer Res. 2023;8(3):64-71. doi: 10.11648/j.ijcocr.20230803.14

Copy | Download

@article{10.11648/j.ijcocr.20230803.14,
  author = {Beauty Saha and Muhammad Rafiqul Islam and Nazma Azim and Salman Bashar Al Aub and Rashedul Islam and Ahmed Jabeer},
  title = {Association Between Platelet Count and Other Factors in Patients with Stage-IV Non-Small Cell Lung Cancer},
  journal = {International Journal of Clinical Oncology and Cancer Research},
  volume = {8},
  number = {3},
  pages = {64-71},
  doi = {10.11648/j.ijcocr.20230803.14},
  url = {https://doi.org/10.11648/j.ijcocr.20230803.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcocr.20230803.14},
  abstract = {Background: Stage IV non-small-cell lung cancer (NSCLC) means a disease that has spread from the lungs to distant areas of the body like the liver, brain, or bones. An increased platelet count can accompany various cancers including lung cancer. This finding has recently been suggested to indicate a poor prognosis. Preconception on the relation between platelet count and other associated factors in patients with stage-IV non-small cell lung cancer may be a potential associated indicator in managing such patients. Aim of the study: This study aimed to evaluate the relationship between platelet count and other associated factors in patients with stage-IV non-small cell lung cancer (NSCLC). Methods: This prospective observational study was conducted at the National Institute of Cancer Research & Hospital (NICRH), Dhaka, Bangladesh during the period from September 2019 to August 2020. A total of 108 patients were enrolled purposively. Detailed history taking and thorough physical examination was done along with relevant investigations. Data were collected by semi-structured questionnaire and analysis was done by SPSS, version 21.0. Results: The mean age of the patients was found 56.4±12.2 years and the majority (79.6%) of patients were male. The highest number of participants (40.7%) were symptomatic; in bed, >50% of the day, almost two-thirds (59.3%) had <5% weight loss, and almost three fourth (69.4%) had squamous cell carcinoma. At the time of the first assessment, 75 (69.4%) patients had normal and 33 (30.6%) had elevated platelet count levels, age, sex, and histological type were statistically not significant between normal and elevated platelet count level groups. But performance status and weight loss were statistically significant (p<0.05) between the two groups. According to univariate analysis, age, performance status at presentation, weight loss of more than 10% for 3 months and platelet count before the start of treatment were all significant predictors for overall survival. Conclusion: As per the findings of this study we can conclude that there has no significant correlation of platelet count with age, sex or histological types of NSCLC patients. But with performance status and weight loss, there may have a statistically significant correlation in such patients.},
 year = {2023}
}

Copy | Download